The meningococcal vaccine candidate neisserial surface protein A (NspA) binds to factor H and enhances meningococcal resistance to complement.

Complement forms an important arm of innate immunity against invasive meningococcal infections. Binding of the alternative complement pathway inhibitor factor H (fH) to fH-binding protein (fHbp) is one mechanism meningococci employ to limit complement activation on the bacterial surface. fHbp is a l...

Full description

Bibliographic Details
Main Authors: Lisa A Lewis, Jutamas Ngampasutadol, Ruth Wallace, Jane E A Reid, Ulrich Vogel, Sanjay Ram
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2010-07-01
Series:PLoS Pathogens
Online Access:http://europepmc.org/articles/PMC2912398?pdf=render
id doaj-0377f608a48d4721a4d0121bc9838d6e
record_format Article
spelling doaj-0377f608a48d4721a4d0121bc9838d6e2020-11-25T00:11:59ZengPublic Library of Science (PLoS)PLoS Pathogens1553-73661553-73742010-07-0167e100102710.1371/journal.ppat.1001027The meningococcal vaccine candidate neisserial surface protein A (NspA) binds to factor H and enhances meningococcal resistance to complement.Lisa A LewisJutamas NgampasutadolRuth WallaceJane E A ReidUlrich VogelSanjay RamComplement forms an important arm of innate immunity against invasive meningococcal infections. Binding of the alternative complement pathway inhibitor factor H (fH) to fH-binding protein (fHbp) is one mechanism meningococci employ to limit complement activation on the bacterial surface. fHbp is a leading vaccine candidate against group B Neisseria meningitidis. Novel mechanisms that meningococci employ to bind fH could undermine the efficacy of fHbp-based vaccines. We observed that fHbp deletion mutants of some meningococcal strains showed residual fH binding suggesting the presence of a second receptor for fH. Ligand overlay immunoblotting using membrane fractions from one such strain showed that fH bound to a approximately 17 kD protein, identified by MALDI-TOF analysis as Neisserial surface protein A (NspA), a meningococcal vaccine candidate whose function has not been defined. Deleting nspA, in the background of fHbp deletion mutants, abrogated fH binding and mAbs against NspA blocked fH binding, confirming NspA as a fH binding molecule on intact bacteria. NspA expression levels vary among strains and expression correlated with the level of fH binding; over-expressing NspA enhanced fH binding to bacteria. Progressive truncation of the heptose (Hep) I chain of lipooligosaccharide (LOS), or sialylation of lacto-N-neotetraose LOS both increased fH binding to NspA-expressing meningococci, while expression of capsule reduced fH binding to the strains tested. Similar to fHbp, binding of NspA to fH was human-specific and occurred through fH domains 6-7. Consistent with its ability to bind fH, deleting NspA increased C3 deposition and resulted in increased complement-dependent killing. Collectively, these data identify a key complement evasion mechanism with important implications for ongoing efforts to develop meningococcal vaccines that employ fHbp as one of its components.http://europepmc.org/articles/PMC2912398?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Lisa A Lewis
Jutamas Ngampasutadol
Ruth Wallace
Jane E A Reid
Ulrich Vogel
Sanjay Ram
spellingShingle Lisa A Lewis
Jutamas Ngampasutadol
Ruth Wallace
Jane E A Reid
Ulrich Vogel
Sanjay Ram
The meningococcal vaccine candidate neisserial surface protein A (NspA) binds to factor H and enhances meningococcal resistance to complement.
PLoS Pathogens
author_facet Lisa A Lewis
Jutamas Ngampasutadol
Ruth Wallace
Jane E A Reid
Ulrich Vogel
Sanjay Ram
author_sort Lisa A Lewis
title The meningococcal vaccine candidate neisserial surface protein A (NspA) binds to factor H and enhances meningococcal resistance to complement.
title_short The meningococcal vaccine candidate neisserial surface protein A (NspA) binds to factor H and enhances meningococcal resistance to complement.
title_full The meningococcal vaccine candidate neisserial surface protein A (NspA) binds to factor H and enhances meningococcal resistance to complement.
title_fullStr The meningococcal vaccine candidate neisserial surface protein A (NspA) binds to factor H and enhances meningococcal resistance to complement.
title_full_unstemmed The meningococcal vaccine candidate neisserial surface protein A (NspA) binds to factor H and enhances meningococcal resistance to complement.
title_sort meningococcal vaccine candidate neisserial surface protein a (nspa) binds to factor h and enhances meningococcal resistance to complement.
publisher Public Library of Science (PLoS)
series PLoS Pathogens
issn 1553-7366
1553-7374
publishDate 2010-07-01
description Complement forms an important arm of innate immunity against invasive meningococcal infections. Binding of the alternative complement pathway inhibitor factor H (fH) to fH-binding protein (fHbp) is one mechanism meningococci employ to limit complement activation on the bacterial surface. fHbp is a leading vaccine candidate against group B Neisseria meningitidis. Novel mechanisms that meningococci employ to bind fH could undermine the efficacy of fHbp-based vaccines. We observed that fHbp deletion mutants of some meningococcal strains showed residual fH binding suggesting the presence of a second receptor for fH. Ligand overlay immunoblotting using membrane fractions from one such strain showed that fH bound to a approximately 17 kD protein, identified by MALDI-TOF analysis as Neisserial surface protein A (NspA), a meningococcal vaccine candidate whose function has not been defined. Deleting nspA, in the background of fHbp deletion mutants, abrogated fH binding and mAbs against NspA blocked fH binding, confirming NspA as a fH binding molecule on intact bacteria. NspA expression levels vary among strains and expression correlated with the level of fH binding; over-expressing NspA enhanced fH binding to bacteria. Progressive truncation of the heptose (Hep) I chain of lipooligosaccharide (LOS), or sialylation of lacto-N-neotetraose LOS both increased fH binding to NspA-expressing meningococci, while expression of capsule reduced fH binding to the strains tested. Similar to fHbp, binding of NspA to fH was human-specific and occurred through fH domains 6-7. Consistent with its ability to bind fH, deleting NspA increased C3 deposition and resulted in increased complement-dependent killing. Collectively, these data identify a key complement evasion mechanism with important implications for ongoing efforts to develop meningococcal vaccines that employ fHbp as one of its components.
url http://europepmc.org/articles/PMC2912398?pdf=render
work_keys_str_mv AT lisaalewis themeningococcalvaccinecandidateneisserialsurfaceproteinanspabindstofactorhandenhancesmeningococcalresistancetocomplement
AT jutamasngampasutadol themeningococcalvaccinecandidateneisserialsurfaceproteinanspabindstofactorhandenhancesmeningococcalresistancetocomplement
AT ruthwallace themeningococcalvaccinecandidateneisserialsurfaceproteinanspabindstofactorhandenhancesmeningococcalresistancetocomplement
AT janeeareid themeningococcalvaccinecandidateneisserialsurfaceproteinanspabindstofactorhandenhancesmeningococcalresistancetocomplement
AT ulrichvogel themeningococcalvaccinecandidateneisserialsurfaceproteinanspabindstofactorhandenhancesmeningococcalresistancetocomplement
AT sanjayram themeningococcalvaccinecandidateneisserialsurfaceproteinanspabindstofactorhandenhancesmeningococcalresistancetocomplement
AT lisaalewis meningococcalvaccinecandidateneisserialsurfaceproteinanspabindstofactorhandenhancesmeningococcalresistancetocomplement
AT jutamasngampasutadol meningococcalvaccinecandidateneisserialsurfaceproteinanspabindstofactorhandenhancesmeningococcalresistancetocomplement
AT ruthwallace meningococcalvaccinecandidateneisserialsurfaceproteinanspabindstofactorhandenhancesmeningococcalresistancetocomplement
AT janeeareid meningococcalvaccinecandidateneisserialsurfaceproteinanspabindstofactorhandenhancesmeningococcalresistancetocomplement
AT ulrichvogel meningococcalvaccinecandidateneisserialsurfaceproteinanspabindstofactorhandenhancesmeningococcalresistancetocomplement
AT sanjayram meningococcalvaccinecandidateneisserialsurfaceproteinanspabindstofactorhandenhancesmeningococcalresistancetocomplement
_version_ 1725401961215295488